EP3140429A4 - Methods and compositions for scd, crt, crt-d, or sca therapy identification and/or selection - Google Patents

Methods and compositions for scd, crt, crt-d, or sca therapy identification and/or selection Download PDF

Info

Publication number
EP3140429A4
EP3140429A4 EP15789936.0A EP15789936A EP3140429A4 EP 3140429 A4 EP3140429 A4 EP 3140429A4 EP 15789936 A EP15789936 A EP 15789936A EP 3140429 A4 EP3140429 A4 EP 3140429A4
Authority
EP
European Patent Office
Prior art keywords
crt
scd
sca
compositions
selection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15789936.0A
Other languages
German (de)
French (fr)
Other versions
EP3140429A1 (en
EP3140429B1 (en
Inventor
Orhan Soykan
Tara Nahey
Jeffrey Lande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Soykan Orhan
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soykan Orhan, Medtronic Inc filed Critical Soykan Orhan
Publication of EP3140429A1 publication Critical patent/EP3140429A1/en
Publication of EP3140429A4 publication Critical patent/EP3140429A4/en
Application granted granted Critical
Publication of EP3140429B1 publication Critical patent/EP3140429B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP15789936.0A 2014-05-05 2015-04-28 Methods for scd, crt, crt-d, or sca therapy identification and/or selection Active EP3140429B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988323P 2014-05-05 2014-05-05
US201562104098P 2015-01-16 2015-01-16
PCT/US2015/028095 WO2015171370A1 (en) 2014-05-05 2015-04-28 Methods and compositions for scd, crt, crt-d, or sca therapy identification and/or selection

Publications (3)

Publication Number Publication Date
EP3140429A1 EP3140429A1 (en) 2017-03-15
EP3140429A4 true EP3140429A4 (en) 2018-04-04
EP3140429B1 EP3140429B1 (en) 2020-02-19

Family

ID=54354827

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15789936.0A Active EP3140429B1 (en) 2014-05-05 2015-04-28 Methods for scd, crt, crt-d, or sca therapy identification and/or selection

Country Status (4)

Country Link
US (2) US20150315644A1 (en)
EP (1) EP3140429B1 (en)
CN (1) CN106460062A (en)
WO (1) WO2015171370A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI607332B (en) * 2016-12-21 2017-12-01 國立臺灣師範大學 Correlation between persistent organic pollutants and microRNAs station
CN106868126B (en) * 2017-02-20 2020-06-19 深圳美因医学检验实验室 Fluorescent quantitative PCR detection kit and detection method
AU2019280867A1 (en) * 2018-06-06 2021-01-07 Lexent Bio, Inc. Methods for fingerprinting of biological samples
US20220333169A1 (en) * 2019-09-13 2022-10-20 Henry Ford Health System Polygenic Score for Cardiac Heart Failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076690A2 (en) * 2003-02-19 2004-09-10 Universit�T Duisburg-Essen Use of a mutation in the human gnas gene for predicting risks of disease, courses of diseases, and for predicting the response to treatments of disease
US20110143345A1 (en) * 2007-11-14 2011-06-16 Medtronic, Inc. Genetic Markers for SCD or SCA Therapy Selection
WO2012094651A2 (en) * 2011-01-06 2012-07-12 The Board Of Trustees Of The University Of Illiois Scn5a splice variants for use in methods relating to sudden cardiac death and need for implanted cadiac defibrillators

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1115210A (en) 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
FR2495939B1 (en) 1980-12-11 1985-10-11 Merieux Inst PROCESS FOR THE PURIFICATION OF STREPTOCOCCUS PNEUMONIAE POLYOSIDES AND VACCINE BASED ON THE PURIFIED POLYOSIDES
BE889979A (en) 1981-08-14 1982-02-15 Smith Kline Rit PROCESS FOR THE PREPARATION OF PURIFIED ANTIGENIC CAPSULAR BACTERIAL POLYSACCHARIDES, PRODUCTS OBTAINED AND THEIR USE
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
HU220795B1 (en) 1991-09-20 2002-05-28 Amgen Inc. Glialcell derived neurotrophic factor proteins and devices and pharmaceutical preparations for preventing and treating neural cell damage
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
CA2247800A1 (en) 1997-03-27 1998-10-01 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
PT1493439E (en) 1997-04-02 2012-01-10 Brigham & Womens Hospital Means of ascertaining an individual` s risk profile for atherosclerotic disease
WO1998046273A2 (en) 1997-04-17 1998-10-22 Paola Leone Delivery system for gene therapy to the brain
US7048716B1 (en) 1997-05-15 2006-05-23 Stanford University MR-compatible devices
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US6099469A (en) 1998-06-02 2000-08-08 Armstrong; E. Glenn Reflex algorithm for early and cost effective diagnosis of myocardial infractions suitable for automated diagnostic platforms
US6233487B1 (en) 1999-06-08 2001-05-15 Impulse Dynamics N.V. Apparatus and method for setting the parameters of an alert window used for timing the delivery of ETC signals to a heart under varying cardiac conditions
DE1233364T1 (en) 1999-06-25 2003-04-10 Genaissance Pharmaceuticals Method for producing and using haplotype data
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
WO2002052033A1 (en) 2000-12-22 2002-07-04 Joslin Diabetes Center, Inc. Pkc monocyte assay
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US6500630B2 (en) 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
US6602241B2 (en) 2001-01-17 2003-08-05 Transvascular, Inc. Methods and apparatus for acute or chronic delivery of substances or apparatus to extravascular treatment sites
WO2002063959A1 (en) 2001-02-09 2002-08-22 The Schepens Eye Research Institute Methods and compositions for stimulating axon regeneration and prventing neuronal cell degeneration
US20020165161A1 (en) 2001-05-04 2002-11-07 Surromed, Inc. Chemokine-binding proteins for treating congestive heart failure
DE60234057D1 (en) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc COMPOSITIONS AND METHODS FOR MODULATING TRANSPORT BY THE BLOOD-BRAIN BARRIER
WO2003044057A2 (en) 2001-11-21 2003-05-30 Genset S.A. Use of obg3 for promoting central nervous system remyelination
US20030019063A1 (en) 2002-09-26 2003-01-30 Homedics, Inc. Picture display toothbrush
WO2006002283A1 (en) 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
DE10348600A1 (en) * 2003-02-19 2004-09-02 Universität Duisburg-Essen Use of a gene modification in the human GNAS1 gene to predict disease risks, disease courses and to predict the response to disease therapies
EP1608782A2 (en) * 2003-03-10 2005-12-28 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US20040236603A1 (en) 2003-05-22 2004-11-25 Biospect, Inc. System of analyzing complex mixtures of biological and other fluids to identify biological state information
WO2005017652A2 (en) 2003-08-05 2005-02-24 Rosetta Inpharmatics, Llc Computer systems and methods for inferring causality from cellular constituent abundance data
US20050181386A1 (en) 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
EP1723432A1 (en) 2004-02-05 2006-11-22 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
US7608458B2 (en) 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
DE102004026330A1 (en) 2004-05-26 2005-12-15 Universität Duisburg-Essen Use of gene modification in the human GNAQ gene to predict disease risks, disease trajectories and predict disease response
US8335652B2 (en) 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US20050287574A1 (en) * 2004-06-23 2005-12-29 Medtronic, Inc. Genetic diagnostic method for SCD risk stratification
US8027791B2 (en) 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US7361468B2 (en) 2004-07-02 2008-04-22 Affymetrix, Inc. Methods for genotyping polymorphisms in humans
WO2006132983A2 (en) 2005-06-03 2006-12-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential expression of molecules associated with vascular disease risk
US20070082347A1 (en) 2005-06-08 2007-04-12 Myriad Genetics, Incorporated Gene variants and use thereof
US8236497B2 (en) * 2005-09-21 2012-08-07 Joslin Diabetes Center, Inc. Methods of diagnosing cardiovascular disease
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
EP2102651A4 (en) 2006-11-30 2010-11-17 Navigenics Inc Genetic analysis systems and methods
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20110143956A1 (en) 2007-11-14 2011-06-16 Medtronic, Inc. Diagnostic Kits and Methods for SCD or SCA Therapy Selection
WO2009064973A2 (en) 2007-11-14 2009-05-22 Medtronic Inc. Diagnostic kits and methods for scd or sca therapy selection
WO2010132546A2 (en) 2009-05-12 2010-11-18 Medtronic, Inc. Sca risk stratification by predicting patient response to anti-arrhythmics
WO2012054653A2 (en) 2010-10-19 2012-04-26 Medtronic, Inc. Diagnostic kits, genetic markers, and methods for scd or sca therapy selection
CN103757091B (en) * 2013-09-13 2016-09-07 广州市体育科学研究所 Sudden cardiac death rapid gene detection kit and detection method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076690A2 (en) * 2003-02-19 2004-09-10 Universit�T Duisburg-Essen Use of a mutation in the human gnas gene for predicting risks of disease, courses of diseases, and for predicting the response to treatments of disease
US20110143345A1 (en) * 2007-11-14 2011-06-16 Medtronic, Inc. Genetic Markers for SCD or SCA Therapy Selection
WO2012094651A2 (en) * 2011-01-06 2012-07-12 The Board Of Trustees Of The University Of Illiois Scn5a splice variants for use in methods relating to sudden cardiac death and need for implanted cadiac defibrillators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEINRICH WIENEKE ET AL: "Polymorphisms associated with ventricular tachyarrhythmias: rationale, design, and endpoints of the ?diagnostic data influence on disease management and relation of genomics to ventricular tachyarrhythmias in implantable cardioverter/defibrillator patients (DISCOVERY)? study", EUROPACE, W.B. SAUNDERS, GB, vol. 12, no. 3, 1 March 2010 (2010-03-01), pages 424 - 429, XP002665310, ISSN: 1099-5129, [retrieved on 20100205], DOI: 10.1093/EUROPACE/EUP444 *
See also references of WO2015171370A1 *

Also Published As

Publication number Publication date
CN106460062A (en) 2017-02-22
US20150315644A1 (en) 2015-11-05
US20190017120A1 (en) 2019-01-17
EP3140429A1 (en) 2017-03-15
EP3140429B1 (en) 2020-02-19
US11312994B2 (en) 2022-04-26
WO2015171370A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
EP3551285A4 (en) Defibrillator
HK1251551A1 (en) Azetidine derivative, preparation method therefor, and use thereof
ZA201701465B (en) Egfr inhibitor, and preparation and application thereof
EP3317409A4 (en) Crispr/cas9-based treatments
EP3355768A4 (en) Quantitative heart testing
EP3158528A4 (en) Trip planning and implementation
EP3161124A4 (en) Endophytes, associated compositions, and methods of use thereof
EP3110503A4 (en) External defibrillator
EP3091911A4 (en) Resection guides, implants and methods
EP3153169A4 (en) Method for treating tumour, pharmaceutical composition and medicine box kit
EP3331612A4 (en) Methods and compositions for tumor therapy
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
EP3221529A4 (en) Gypsum panels, cores, and methods for the manufacture thereof
EP3552017A4 (en) Compounds, compositions and methods
EP3285210A4 (en) Value bill identifying method
EP3335157A4 (en) Two-piece transaction card construction
EP3112351A4 (en) Naphthylamide compound, preparation method and use thereof
EP3097990A4 (en) Cold-rolling facility
EP3157016A4 (en) Scintillator, preparing method thereof, and application thereof
EP3367938A4 (en) Self-compressing implant
EP3381919A4 (en) Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof
EP3122292A4 (en) Hammer toe implant
EP3140429A4 (en) Methods and compositions for scd, crt, crt-d, or sca therapy identification and/or selection
EP3199526A4 (en) Intermediate for use in synthesizing paroxetine, preparation method for the intermediate, and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/22 20110101ALI20171115BHEP

Ipc: C12Q 1/68 20060101AFI20171115BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180302

RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/22 20110101ALI20180226BHEP

Ipc: C12Q 1/68 20060101AFI20180226BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190214

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015047378

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12Q0001680000

Ipc: C12Q0001688300

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6883 20180101AFI20190712BHEP

INTG Intention to grant announced

Effective date: 20190730

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDTRONIC, INC.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015047378

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1235022

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200519

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200619

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200520

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200712

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1235022

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200219

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015047378

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20201120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200428

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200428

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200219

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230321

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240320

Year of fee payment: 10